AR042262A2 - Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis - Google Patents

Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis

Info

Publication number
AR042262A2
AR042262A2 ARP9501333967A AR33396795A AR042262A2 AR 042262 A2 AR042262 A2 AR 042262A2 AR P9501333967 A ARP9501333967 A AR P9501333967A AR 33396795 A AR33396795 A AR 33396795A AR 042262 A2 AR042262 A2 AR 042262A2
Authority
AR
Argentina
Prior art keywords
preparation
treatment
dihydroestrone
aterosclerosis
medicinal product
Prior art date
Application number
ARP9501333967A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR042262A2 publication Critical patent/AR042262A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Abstract

Uso de un compuesto para la preparación de un medicamento para el tratamiento de un paciente que tiene aterosclerosis para eliminar lesiones arteriales que atienden al desarrollo de aterosclerosis, en el cual el compuesto usado es 8,9-dihidroestrona.
ARP9501333967A 1992-02-26 1995-10-24 Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis AR042262A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/841,694 US5210081A (en) 1992-02-26 1992-02-26 Alkali metal 8,9-dehydroestrone sulfate esters

Publications (1)

Publication Number Publication Date
AR042262A2 true AR042262A2 (es) 2005-06-15

Family

ID=25285489

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP9501333967A AR042262A2 (es) 1992-02-26 1995-10-24 Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ARP030104530A AR042345A2 (es) 1992-02-26 2003-12-09 Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030104530A AR042345A2 (es) 1992-02-26 2003-12-09 Un procedimiento para la preparacion de una composicion farmaceutica para el tratamiento de aterosclerosis que contiene 8.9 - dehidroesterona o sus sales de la misma

Country Status (22)

Country Link
US (3) US5210081A (es)
EP (2) EP0628052B1 (es)
JP (1) JP3715645B2 (es)
KR (1) KR100256861B1 (es)
AR (2) AR042262A2 (es)
AT (2) ATE174342T1 (es)
AU (2) AU677181B2 (es)
CA (1) CA2089707A1 (es)
DE (2) DE69334073T2 (es)
DK (2) DK0864583T3 (es)
ES (2) ES2274555T3 (es)
FI (1) FI115915B (es)
GR (1) GR3029620T3 (es)
HK (2) HK1011369A1 (es)
HU (2) HUT67553A (es)
LV (1) LV12240B (es)
MX (1) MX9300969A (es)
PT (1) PT864583E (es)
SG (1) SG49715A1 (es)
TW (1) TW257677B (es)
WO (1) WO1993017036A1 (es)
ZA (1) ZA93746B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE4334823C2 (de) * 1993-10-09 1998-09-17 Schering Ag Verfahren zur Herstellung von Schwefelsäurehalbestern von Estrogenen
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5998639A (en) * 1995-11-06 1999-12-07 Akzo Nobel, N.V. Sulfatation of estrogen mixtures
AU703814B2 (en) * 1995-12-04 1999-04-01 Wyeth Antioxidant
DE19631543C1 (de) * 1996-07-25 1997-11-20 Schering Ag Verfahren zur Herstellung von 3-Sulfatoxy-estra-1,3,5(10)-trien-Derivaten I
DE19631542C1 (de) * 1996-07-25 1997-08-28 Schering Ag Verfahren zur Herstellung von 3-Sulfatoxy-estra-1,3,5(10)-trien-Derivaten II
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
ID18256A (id) * 1996-09-16 1998-03-19 American Home Prod Penggunaan dari 8,9-dehidro estron sebagai estrogen dengan hasil netral pada tingkat prolaktin
AR014096A1 (es) * 1996-10-11 2001-02-07 Wyeth Corp 17 alfa,8,9-deshidroestradiol y 17 beta delta 8,9 deshidroestradiol, el uso de los mismos para la manufactura de un medicamento, una composicionfarmaceutica que los comprende y un procedimiento para su preparacion.
ZA979204B (en) * 1996-10-16 1999-04-14 American Home Prod Use of 8,9-dehydroestrone in treating vasomotor symptoms
IL124213A (en) * 1997-05-02 2004-12-15 Akzo Nobel Nv Sulfation of estrogen mixtures
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030158432A1 (en) * 2002-01-08 2003-08-21 Leonard Thomas W. Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex
US8349819B2 (en) * 2002-10-09 2013-01-08 Dr. Reddy's Laboratories New York, Inc. Steroid extraction process from urine sources
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
US20040259851A1 (en) * 2003-04-11 2004-12-23 Leonard Thomas W. Methods of administering estrogens and progestins
CA2566771A1 (en) * 2004-06-07 2005-12-22 Wyeth Sugar coatings and methods therefor
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
AU2006330846A1 (en) * 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
AU2007316458A1 (en) * 2006-11-07 2008-05-15 Wyeth Sugar coatings and methods therefor
CL2008000095A1 (es) * 2007-01-12 2008-05-16 Wyeth Corp Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
WO2008100769A2 (en) * 2007-02-09 2008-08-21 Wyeth Process for selective sulfation of aromatic hydroxyl groups
US7902147B2 (en) * 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
AR078785A1 (es) 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US3079410A (en) * 1960-04-02 1963-02-26 Hoechst Ag Process for stabilizing anionic and cationic ester salts of 21-hydroxy-20-ketosteroids in an aqueous solution
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE1200476B (de) * 1961-04-10 1965-09-09 Frosst & Co Charles E Stabilisierung von trockenen Zubereitungen synthetischer Alkalisalze von OEstronsulfat
US3551459A (en) * 1962-10-04 1970-12-29 Herchel Smith 13-methyl-8-isogonanes
US3394153A (en) * 1965-08-18 1968-07-23 Merck & Co Inc Process for the preparation of d, 1-8-dehydroestrone, and intermediates obtained therefrom
NL6805153A (es) * 1968-04-10 1969-10-14
US3644618A (en) * 1968-10-29 1972-02-22 Frosst & Co Charles E Stable composition of synthetic sodium estrone sulfate
US3608077A (en) * 1969-11-13 1971-09-21 Syntex Corp Stabilization of metal steroid alcohol sulfates
US3649621A (en) * 1969-12-19 1972-03-14 American Home Prod Novel 3-cyclopentyl ethers of 13-alkylgon-poly-enes
GB1451109A (en) * 1973-08-17 1976-09-29 Rech Et Dapplications Scient S Derivatives of oestrone and their use in therapy
GB1528321A (en) * 1975-07-07 1978-10-11 Leo Ab Acylation process for the preparation of phenolic n,n-di-substituted carbamate esters
SE439586B (sv) * 1975-09-05 1985-06-24 Kanebo Ltd Sett att framstella ett stabilt farmaceutiskt torrpreparat av ett alkalimetallsalt av dehydroepiandrosteronsulfat
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters

Also Published As

Publication number Publication date
FI943903A (fi) 1994-08-25
FI943903A0 (fi) 1994-08-25
PT864583E (pt) 2007-01-31
ES2125975T3 (es) 1999-03-16
EP0628052B1 (en) 1998-12-09
US5288717A (en) 1994-02-22
HU9402457D0 (en) 1994-10-28
ATE342272T1 (de) 2006-11-15
HK1011369A1 (en) 1999-07-09
EP0864583B1 (en) 2006-10-11
DE69334073D1 (de) 2006-11-23
US6169082B1 (en) 2001-01-02
DK0864583T3 (da) 2006-12-04
LV12240B (en) 1999-06-20
KR950700318A (ko) 1995-01-16
AU2007697A (en) 1997-07-03
MX9300969A (es) 1993-09-01
EP0628052A1 (en) 1994-12-14
DE69334073T2 (de) 2007-02-01
AU3726093A (en) 1993-09-13
ATE174342T1 (de) 1998-12-15
DE69322497T2 (de) 1999-05-06
JPH07504197A (ja) 1995-05-11
EP0864583A2 (en) 1998-09-16
GR3029620T3 (en) 1999-06-30
HUT67553A (en) 1995-04-28
EP0864583A3 (en) 2004-07-21
WO1993017036A1 (en) 1993-09-02
JP3715645B2 (ja) 2005-11-09
SG49715A1 (en) 1998-06-15
LV12240A (lv) 1999-03-20
AU677181B2 (en) 1997-04-17
HK1020282A1 (en) 2000-04-07
FI115915B (fi) 2005-08-15
DK0628052T3 (da) 1999-07-12
KR100256861B1 (ko) 2000-08-01
US5210081A (en) 1993-05-11
CA2089707A1 (en) 1993-08-27
TW257677B (es) 1995-09-21
ZA93746B (en) 1994-08-03
ES2274555T3 (es) 2007-05-16
AR042345A2 (es) 2005-06-15
DE69322497D1 (de) 1999-01-21
HU211971A9 (en) 1996-01-29
AU711571B2 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2000428T3 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
HU9300636D0 (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
ES2055685T3 (es) Procedimiento para la obtencion de un medicamento que contiene ibuprofen.
AR004486A1 (es) Uso de tripicolinato cromico en la preparacion de un medicamento
ATE181505T1 (de) Phosphozucker enthaltende pharmazeutische zubereitung
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2145803T3 (es) Productos para la aplicacion de dosis inicialmente elevadas de cetrorelix y preparacion de un envase combinado para empleo en la terapia de enfermedades.
NO952900D0 (no) Kompositt inneholdende tandospiron eller analoger av samme
BR9106272A (pt) Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo
KR910009267A (ko) 우울증의 치료방법
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2151922T3 (es) Uso de aspirina para la fabricacion de un medicamento para mejorar la perfusion sanguinea en el utero.
SE9404568D0 (sv) The use of inositoltrisphosphate for the preparing of medicaments
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
MX9300767A (es) Derivados del acido amidazolilpropenoico sustituidos por sulfonilbencilo, medicamentos que los contienen y procedimiento para la obtencion de tales medicamentos.
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
ES2122005T3 (es) Medicamento que contiene (-)-metrifonato.
AR002946A1 (es) Un conjunto para uso en el tratamiento o la prevencion de la osteoporosis en los mamiferos de acuerdo con una dieta ciclica.